In a recent development, the United States Drug Enforcement Administration (DEA) and the Substance Abuse and Mental Health Services Administration (SAMHSA) have once again extended flexibilities allowing for the prescription of controlled substances through telemedicine without the necessity for an initial in-person visit. Initially provided as a response to the ongoing COVID-19 public health emergency (PHE), this extension is now set to remain in place until the end of 2024.
Introduced as a strategic measure to manage the risks associated with the pandemic, the provision for telemedicine prescriptions has proven an effective protocol in safeguarding the health of patients and healthcare providers while ensuring necessary medications remain accessible.
A notable aspect of this extension is that the DEA is in the process of finalising a rule that will address the matter of telemedicine prescriptions in a comprehensive manner. This implies the imminent establishment of a more structured regulatory framework around the issue.
This extended flexibility by the DEA and SAMHSA speaks to a possible shift in the overall approach towards healthcare delivery, particularly when it comes to navigating the challenges presented by public health crises such as the ongoing pandemic.
For legal professionals advising healthcare providers, pharmaceutical companies and others in the health sector, the implications of these developments could be significant, as it opens up possible new regulatory scenarios to anticipate and navigate.
Further details can be found in the full report provided by McDermott Will & Emery on JDSupra.